Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | EVP, Chief Financial Officer | March 02, 2023 | March 06, 2023 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Chief Financial Officer | May 01, 2026 | May 01, 2026 |
| Zoetis Inc.ZTS · Entity 679 | EVP, CFO & COO | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 177,899 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Tax withholding · Disposed 1,061 · Balance 177,899 F1: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 2, 2023 from the settlement of vested restricted stock units granted on March 2, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 2, 2023 from the settlement of vested restricted stock units granted on March 2, 2022.
GE HealthCare Technologies Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 87,471 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Purchase · Acquired 3,310 · Balance 87,471 F1: The price reported represents the weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $60.59 to $60.60, inclusive. The Reporting Person undertakes to provide to GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $60.59 to $60.60, inclusive. The Reporting Person undertakes to provide to GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Zoetis Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 81,063 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 81,063 · Balance 81,063 F1: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2: Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock. F3: One-third of the total number of RSUs will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, August 31, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Notwithstanding the foregoing, if the Reporting Person's employment with the Company is terminated without Cause (as defined in the Zoetis Executive Severance Plan) prior to the first vesting date, one-third of the RSUs will accelerate and vest as of the date of such termination and will be settled in accordance with the applicable award agreement. F4: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs").
F2: Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock.
F3: One-third of the total number of RSUs will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, August 31, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Notwithstanding the foregoing, if the Reporting Person's employment with the Company is terminated without Cause (as defined in the Zoetis Executive Severance Plan) prior to the first vesting date, one-third of the RSUs will accelerate and vest as of the date of such termination and will be settled in accordance with the applicable award agreement.
F4: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:34 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 81,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-060136 · wk-form4_1788381284.xml · derivative · entry 1 SACCARO JAMES · CIK 0001593636 · EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,063 Underlying: Common Stock · 81,063 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: One-third of the total number of RSUs will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, August 31, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Notwithstanding the foregoing, if the Reporting Person's employment with the Company is terminated without Cause (as defined in the Zoetis Executive Severance Plan) prior to the first vesting date, one-third of the RSUs will accelerate and vest as of the date of such termination and will be settled in accordance with the applicable award agreement. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| May 01, 2026 Filed May 1, 2026 15:38 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | PurchaseCommon Stock, par value $0.01 per share | 3,310 | $60.60 | $200,585.01 |
DisclosureSEC source: 0001593636-26-000008 · wk-form4_1777649933.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,471 F1 · price: The price reported represents the weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $60.59 to $60.60, inclusive. The Reporting Person undertakes to provide to GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:23 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 32,797 | $0.00 Strike: $80.16 | $0.00 |
DisclosureSEC source: 0001593636-26-000006 · wk-form4_1772659390.xml · derivative · entry 2 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,797 Underlying: Common Stock, par value $0.01 per share · 32,797 shares Expires 2036-03-02 F3 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029. F3 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:23 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 12,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-26-000006 · wk-form4_1772659390.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,161 F1 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. F2 · shares: Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:14 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 8,570 | $79.20 | $678,744.00 |
DisclosureSEC source: 0001593636-26-000004 · wk-form4_1771373665.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,686 F2 · shares: Withholding of shares of GE HealthCare common stock to satisfy tax withholding obligations in connection with the vesting of PSUs. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:14 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 22,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-26-000004 · wk-form4_1771373665.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,256 F1 · shares: Performance stock units ("PSUs") granted on March 1, 2023, by GE HealthCare Technologies Inc. ("GE HealthCare"). Each PSU represented the right to receive one share of GE HealthCare common stock. The applicable performance criteria were satisfied and certified by GE HealthCare's Talent, Culture, and Compensation Committee and the PSUs vested on February 12, 2026. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 23:51 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 948 | $78.97 | $74,863.56 |
DisclosureSEC source: 0001593636-26-000002 · wk-form4_1770162715.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,646 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:12 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 1,498 | $73.73 | $110,447.54 |
DisclosureSEC source: 0001593636-25-000006 · wk-form4_1756930348.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,594 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:12 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 1,740 | $73.73 | $128,290.20 |
DisclosureSEC source: 0001593636-25-000006 · wk-form4_1756930348.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,092 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 9,712 | $70.54 | $685,084.48 |
DisclosureSEC source: 0001932393-25-000036 · wk-form4_1748981313.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,832 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:38 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 32,252 | $0.00 Strike: $86.45 | $0.00 |
DisclosureSEC source: 0001628280-25-010700 · wk-form4_1741221515.xml · derivative · entry 2 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,252 Underlying: Common Stock, par value $0.01 per share · 32,252 shares Expires 2035-03-03 F3 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 3, 2026, 33% will become exercisable on September 3, 2027, and 34% will become exercisable on September 3, 2028, subject to certain conditions. F3 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 3, 2026, 33% will become exercisable on September 3, 2027, and 34% will become exercisable on September 3, 2028, subject to certain conditions. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:38 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 11,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010700 · wk-form4_1741221515.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,544 F1 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. F2 · shares: Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 3, 2026, 33% will vest on September 3, 2027, and 34% will vest on September 3, 2028. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:26 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 934 | $88.30 | $82,472.20 |
DisclosureSEC source: 0001628280-25-003744 · wk-form4_1738704370.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,266 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:06 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 1,740 | $84.82 | $147,586.80 |
DisclosureSEC source: 0001628280-24-039302 · wk-form4_1725480388.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,200 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 12:00 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | Tax withholdingCommon Stock, par value $0.01 per share | 8,998 | $78.00 | $701,844.00 |
DisclosureSEC source: 0001628280-24-026476 · wk-form4_1717502409.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,940 F1 · shares: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:55 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 29,141 | $0.00 Strike: $92.72 | $0.00 |
DisclosureSEC source: 0001628280-24-009083 · wk-form4_1709679314.xml · derivative · entry 2 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,141 Underlying: Common Stock, par value $0.01 per share · 29,141 shares Expires 2034-03-01 F3 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2025, 33% will become exercisable on September 1, 2026, and 34% will become exercisable on September 1, 2027, subject to certain conditions. F3 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2025, 33% will become exercisable on September 1, 2026, and 34% will become exercisable on September 1, 2027, subject to certain conditions. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:55 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 10,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009083 · wk-form4_1709679314.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,938 F1 · shares: Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 33% will vest on September 1, 2025, 33% will vest on September 1, 2026, and 34% will vest on September 1, 2027, subject to certain conditions. F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:31 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 54,472 | Not disclosed Strike: $79.83 | Not disclosed |
DisclosureSEC source: 0001628280-23-020935 · wk-form4_1686000668.xml · derivative · entry 5 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,472 Underlying: Common Stock, par value $0.01 per share · 54,472 shares Expires 2033-06-01 F6 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 50% will become exercisable on February 1, 2025 and 50% will become exercisable on February 1, 2026. F6 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 50% will become exercisable on February 1, 2025 and 50% will become exercisable on February 1, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:31 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantEmployee Stock Option (right to buy) · Derivative | 36,176 | Not disclosed Strike: $79.83 | Not disclosed |
DisclosureSEC source: 0001628280-23-020935 · wk-form4_1686000668.xml · derivative · entry 4 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,176 Underlying: Common Stock, par value $0.01 per share · 36,176 shares Expires 2033-06-01 F5 · price: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2024, 33% will become exercisable on September 1, 2025, and 34% will become exercisable on September 1, 2026. F5 · derivative.exercise_date: Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2024, 33% will become exercisable on September 1, 2025, and 34% will become exercisable on September 1, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:31 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 5,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020935 · wk-form4_1686000668.xml · nonDerivative · entry 3 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,693 F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. F4 · shares: Award of restricted stock units with respect to GE HealthCare common stock, of which 50% will vest on February 1, 2025 and 50% will vest on February 1, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:31 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 11,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020935 · wk-form4_1686000668.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,743 F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. F3 · shares: Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 1, 2024, 33% will vest on September 1, 2025, and 34% will vest on September 1, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:31 UTC | GE HealthCare Technologies Inc. GEHC · Entity 1711 | GrantCommon Stock, par value $0.01 per share | 43,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020935 · wk-form4_1686000668.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,843 F1 · shares: Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 50% will vest on June 1, 2024 and 50% will vest on June 1, 2025. F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:13 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 1,061 | $39.62 | $42,036.82 |
DisclosureSEC source: 0001062993-23-006069 · form4.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,899 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 2, 2023 from the settlement of vested restricted stock units granted on March 2, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:09 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 92,109 | $0.00 Strike: $39.06 | $0.00 |
DisclosureSEC source: 0001062993-23-005857 · form4.xml · derivative · entry 2 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,109 Underlying: Common Stock, $1 par value · 92,109 shares Expires 2033-03-01 F2 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on March 1, 2024, the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:09 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 22,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-005857 · form4.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,961 F1 · shares: The reporting person received a grant of restricted stock units which are scheduled to vest in three equal annual installments beginning on March 1, 2024, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 22:13 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 1,059 | $40.50 | $42,889.50 |
DisclosureSEC source: 0001062993-23-003686 · form4.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,744 F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2020 PSUs. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 22:13 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 3,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-003686 · form4.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,803 F1 · shares: Represents shares awarded from the performance share unit award granted on March 20, 2020 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2020 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2020 to December 31, 2022 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 49,613 | $0.00 Strike: $85.23 | $0.00 |
DisclosureSEC source: 0001062993-22-006854 · form4.xml · derivative · entry 2 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,613 Underlying: Common Stock, $1 par value · 49,613 shares Expires 2032-03-02 F2 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on March 2, 2023, the first anniversary of the grant date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 10,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006854 · form4.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,276 F1 · shares: The reporting person received a grant of restricted stock units which are scheduled to vest in three equal annual installments beginning on March 2, 2023, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:17 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 4,807 | $87.75 | $421,814.25 |
DisclosureSEC source: 0001062993-22-004284 · form4.xml · nonDerivative · entry 3 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,574 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of shares in 2019, 2020, and 2021 as part of the 2019 PSUs. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:17 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 7,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004284 · form4.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,381 F2 · shares: Represents shares awarded from the 2019 PSUs. The award provides that fifty percent of the performance share units are earned based on Baxter's Total Shareholder Return (TSR) performance over the Three-Year Performance Period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's TSR during the Three-Year Performance Period. These shares have vested as the Three-Year Performance Period has ended. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:17 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004284 · form4.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,847 F1 · shares: Represents shares awarded from the performance share unit award granted on February 28, 2019 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2019 PSUs). The award provided that fifty percent of the performance share units are earned based on Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's OM during the January 1, 2021 to December 31, 2021 performance period. These shares have vested as the relevant three-year performance period January 1, 2019 to December 31, 2021 (the Three-Year Performance Period) has ended. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:10 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 34,678 | $77.60 | $2,691,012.80 |
DisclosureSEC source: 0001593636-21-000003 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,240 F1 · price: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of restricted stock units granted on September 1, 2017. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 82,369 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0001593636-21-000002 · edgar.xml · derivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,369 Underlying: Common Stock, $1 par value · 82,369 shares Expires 2031-03-03 F1 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on March 3, 2022, the first anniversary of the grant date. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:15 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-21-000001 · edgar.xml · nonDerivative · entry 4 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,458 F4 · shares: Represents shares earned from the performance share unit award granted on February 28, 2019 pursuant to the Equity Plan adopted by Baxter as of such date. The award provides that fifty percent of the performance share units are earned based on Baxter's OM performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2020 to December 31, 2020. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from Janaury 1, 2019 through December 31, 2021). Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:15 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 4,308 | $77.80 | $335,162.40 |
DisclosureSEC source: 0001593636-21-000001 · edgar.xml · nonDerivative · entry 3 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,279 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of shares earned in 2018, 2019, and 2020 as part of the 2018 PSUs. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:15 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 5,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-21-000001 · edgar.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,587 F2 · shares: Represents shares awarded from the 2018 PSUs. The award provides that fifty percent of the performance share units are earned based on Baxter's Total Shareholder Return (TSR) performance over the Three-Year Performance Period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's TSR during the Three-Year Performance Period. These shares have vested as the Three-Year Performance Period has ended. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:15 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 1,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-21-000001 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,346 F1 · shares: Represents shares awarded from the performance share unit award granted on March 1, 2018 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2018 PSUs). The award provides that fifty percent of the performance share units are earned based on Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's OM during the January 1, 2020 to December 31, 2020 performance period. These shares have vested as the relevant three-year performance period January 1, 2018 to December 31, 2020 (the Three-Year Performance Period) has ended. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 21:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 41,322 | $0.00 Strike: $75.75 | $0.00 |
DisclosureSEC source: 0001593636-20-000002 · edgar.xml · derivative · entry 4 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,322 Underlying: Common Stock, $1 par value · 41,322 shares Expires 2030-03-20 F4 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on March 22, 2021, the first anniversary of the grant date. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 10,131 | $84.59 | $856,981.29 |
DisclosureSEC source: 0001593636-20-000002 · edgar.xml · nonDerivative · entry 3 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,029 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 19, 2020 from the settlement of shares earned in 2017, 2018, and 2019 as part of the 2017 PSUs. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 12,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-20-000002 · edgar.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,160 F2 · shares: Represents shares awarded from the 2017 PSUs. The award provides that fifty percent of the performance share units are earned based on Baxter's Total Shareholder Return (TSR) performance over the Three-Year Performance Period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's TSR during the Three-Year Performance Period. These shares have vested as the Three-Year Performance Period has ended. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 4,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-20-000002 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,386 F1 · shares: Represents shares awarded from the performance share unit award granted on March 2, 2017 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2017 PSUs). The award provides that fifty percent of the performance share units are earned based on Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's OM during the Janaury 1, 2019 to December 31, 2019 performance period. These shares have vested as the relevant three-year performance period January 1, 2017 to December 31, 2019 (the Three-Year Performance Period) has ended. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:49 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 3,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-20-000001 · edgar.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,009 F2 · shares: Represents shares earned from the performance share unit award granted on February 28, 2019 pursuant to the Equity Plan adopted by Baxter as of such date. The award provides that fifty percent of the performance share units are earned based on Baxter's OM performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2019 to December 31, 2019. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from Janaury 1, 2019 through December 31, 2021). Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:49 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-20-000001 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,692 F1 · shares: Represents shares earned from the performance share unit award granted on March 1, 2018 pursuant to the Equity Plan adopted by Baxter as of such date. The award provides that fifty percent of the performance share units are earned based on Baxter's OM performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2019 through December 31, 2019. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from January 1, 2018 through December 31, 2020). Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:17 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 89,163 | $0.00 Strike: $74.73 | $0.00 |
DisclosureSEC source: 0001593636-19-000002 · edgar.xml · derivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,163 Underlying: Common Stock, $1 par value · 89,163 shares Expires 2029-02-28 F1 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on February 28, 2020, the first anniversary of the grant date. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 3,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-19-000001 · edgar.xml · nonDerivative · entry 5 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,229 F5 · shares: Represents shares earned from the performance share unit award granted on March 1, 2018 pursuant to the Equity Plan adopted by Baxter as of such date. The award provides that fifty percent of the performance share units are earned based on Baxter's OM performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2018 through December 31, 2018. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from January 1, 2018 through December 31, 2020). Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 4,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-19-000001 · edgar.xml · nonDerivative · entry 4 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,547 F4 · shares: Represents shares earned from the performance share unit award granted on March 2, 2017 pursuant to the Equity Plan adopted by Baxter as of such date. The award provides that fifty percent of the performance share units are earned based on Baxter's OM performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares earned based on Baxter's OM, as assessed from January 1, 2018 to December 31, 2018. These shares are scheduled to vest after the end of the relevant three-year performance period (which runs from Janaury 1, 2017 through December 31, 2019). Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 22,338 | $73.47 | $1,641,172.86 |
DisclosureSEC source: 0001593636-19-000001 · edgar.xml · nonDerivative · entry 3 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,332 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of shares earned in 2016, 2017, and 2018 as part of the 2016 PSUs. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 30,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-19-000001 · edgar.xml · nonDerivative · entry 2 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,670 F2 · shares: Represents shares awarded from the 2016 PSUs. The award provides that fifty percent of the performance share units are earned based on Baxter's Total Shareholder Return (TSR), formerly known as Growth in Shareholder Value, performance over the Three-Year Performance Period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's TSR during the Three-Year Performance Period. These shares have vested as the Three-Year Performance Period has ended. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:14 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 6,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001593636-19-000001 · edgar.xml · nonDerivative · entry 1 SACCARO JAMES · CIK 0001593636 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,343 F1 · shares: Represents shares awarded from the performance share unit award granted on March 3, 2016 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2016 PSUs). The award provides that fifty percent of the performance share units are earned based on Baxter's Adjusted Operating Margin (OM) performance, as assessed annually over a three-year period. One-third of the OM performance share units are allocated to each one-year period. The number of shares reported on this Form 4 represents the shares awarded based on Baxter's OM during the Janaury 1, 2018 to December 31, 2018 performance period. These shares have vested as the relevant three-year performance period January 1, 2016 to December 31, 2018 (the Three-Year Performance Period) has ended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.